IP Verse

Capsule Formulations - EP4233850

The patent EP4233850 was granted to Chemocentryx on Oct 2, 2024. The application was originally filed on Nov 27, 2019 under application number EP23160271A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP4233850

CHEMOCENTRYX
Application Number
EP23160271A
Filing Date
Nov 27, 2019
Status
Granted And Under Opposition
Aug 30, 2024
Grant Date
Oct 2, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

LEK PHARMACEUTICALS DDJun 12, 2025ELKINGTON AND FIFEADMISSIBLE

Patent Citations (18) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
OPPOSITIONEP2381778
OPPOSITIONUS2007298099
OPPOSITIONUS2010311753
OPPOSITIONUS2011086844
OPPOSITIONUS2013312973
OPPOSITIONUS2016346207
OPPOSITIONUS2017246186
OPPOSITIONUS2018179160
OPPOSITIONUS2018280530
OPPOSITIONUS8632763
OPPOSITIONWO2011163640
OPPOSITIONWO2017123716
OPPOSITIONWO2019089534
OTHEREP2381778
OTHERUS2011086844
OTHERWO2017123716
OTHERWO2019089534
SEARCHUS2018179160

Non-Patent Literature (NPL) Citations (46) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- DAVIES J. T., "A Quantitative Kinetic Theory of Emulsion Type, I. Physical Chemistry of the Emulsifying Agent", Gas/Liquid and Liquid/Liquid Interface, (19570000), pages 426 - 438-
DESCRIPTION- GRIFFIN, Journal of the Society of Cosmetic Chemists, (19490000), vol. 1, pages 311 - 326-
DESCRIPTION- GRIFFIN, Journal of the Society of Cosmetic Chemists, (19540000), vol. 5, pages 249 - 256-
DESCRIPTION- HAGEMAN et al., P.N.A.S., (20050000), vol. 102, pages 7227 - 7232-
DESCRIPTION- KOHLER, P. F. et al., J. Immunol., (19670000), vol. 99, pages 1211 - 1216-
DESCRIPTION- MATSUSHITA, M et al., J. Exp. Med., (19920000), vol. 176, pages 1497 - 1502-
DESCRIPTION- OOI, Y. M. et al., J. Immunol., (19800000), vol. 124, pages 2494 - 2498-
DESCRIPTION- SUANKRATAY, C et al., J. Immunol., (19980000), vol. 160, pages 3006 - 3013-
DESCRIPTION- TACK, B. F. et al., Biochemistry, (19790000), vol. 18, pages 1490 - 1497-
DESCRIPTION- Vasculitis, Oxford University Press, (20080000), pages 47 - 53-
DESCRIPTION- V. M. HOLERS, Clinical Immunology: Principles and Practice, Mosby Press, (19960000), pages 363 - 391-
DESCRIPTION- BERGE, S.M. et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science, (19770000), vol. 66, doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560
OPPOSITION- Anonymous Clinicaltrials, "Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis", Clinical Trials - NCT02222155, (20161115), pages 1 - 10, XP093287662-
OPPOSITION- Anonymous, "Controlled Trial Evaluating Avacopan in C3 Glomerulopathy (ACCOLADE)", Clinical Trials - NCT03301467, (20180914), pages 1 - 17, XP093287669-
OPPOSITION- Anonymous, "International Nonproprietary Names for Pharmaceutical Substances (INN) RECOMMENDED International Nonproprietary Names: List 76", WHO DRUG INFORMATION, CH , (20160101), vol. 30, no. 3, ISSN 1010-9609, pages 477 - 544, XP093154418-
OPPOSITION- Anonymous, "NDA Multi-disciplinary Review and Evaluation NDA 214487 Avacopan, ANCA-associated vasculitis (GPA and MPA)", MULTI-DISCIPLINE REVIEW, CENTER FOR DRUG EVALUATION AND RESEARCH, (20181012), pages 1 - 751, MULTI-DISCIPLINE REVIEW, URL: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214487Orig1s000MultidisciplineR.pdf, XP093154439-
OPPOSITION- Anonymous, "Polyethylene glycol 1000", pages 1 - 3, Merck-
OPPOSITION- Anonymous, "Polyoxyethylene Castor Oil Derivatives", Anonymous, Raymond C Rowe; Paul J Sheskey; Marian E Quinn (eds.), Handbook of Pharmaceutical Excipients, UK , Pharmaceutical Press , (20090101), pages 542 - 549, ISBN 978-0-85369-792-3, XP093287628-
OPPOSITION- Arnum Patricia Van, "Solubilizing the Insoluble", Pharmtech, (20101102), pages 1 - 10, Pharmtech, URL: https://www.pharmtech.com/view/solubilizing-insoluble, XP093287634-
OPPOSITION- Aulton Michael E, "Part 1: Scientific principles of dosage form design Dissolution and solubility", Aulton Michael E, Michael E. Aulton, Kevin M. G. Taylor, Aulton's Pharmaceutics E-Book: The Design and Manufacture of Medicines, Edinburgh, Elsevier, (20170601), pages 18 - 36, ISBN 978-0-7020-7005-1, XP093287630-
OPPOSITION- Bhusnure O G, Kazi S B, Gholve, Ansari S N, Kazi, "Solid dispersion ; An ever green method for solubility enhancement of poorly water soluble drugs ", International Journal of Research in Pharmacy And Chemistry, (20140101), vol. 4, no. 4, ISSN 2231-2781, pages 906 - 918, XP093287641-
OPPOSITION- D1a - US 62/579,716 (priority document)-
OPPOSITION- D38 - ChemoCentryx , Inc Protocol CL003_168-
OPPOSITION- D5a - ChemoCentryx, Inc Protocol CL010_168-
OPPOSITION- D5 - ChemoCentryx, Inc. - Protocol CL001_168-
OPPOSITION- Gupta Pardeep K, "Solutions and phase equilibria", Gupta Pardeep K, Felton Linda, Remington, Essentials of Pharmaceutics, GB, Pharmaceutical Press , (20120101), pages 219 - 239, ISBN 978-0-85711-105-0, XP093287656-
OPPOSITION- Hardung H; Djuric D; Ali S, "Combining HME & solubilization: Soluplus(R) - The solid solution", Drug Delivery Technology, US , (20100401), vol. 10, no. 3, ISSN 1537-2898, pages 20 - 27, XP009155307-
OPPOSITION- Miller Dave A, James W. Mcginity, And Robert O. Williams Iii, "13 - Solid Dispersion Technologies", Miller Dave A, James W. Mcginity, And Robert O. Williams Iii, Robert O. Williams III, David R. Taft, Jason T. McConville, Advanced Drug Formulation Design to Optimize Therapeutic Outcomes, US, New York [u.a.] : Informa Healthcare, (20080101), pages 451 - 491, ISBN 978-1-4200-4387-7, XP093287680-
OPPOSITION- Riken, "New method: More pharmaceuticals could benefit from the stabilizing influence of fluorine atoms", Phys Org, (20121005), pages 1 - 2, Phys Org , URL: https://phys.org/news/2012-10-method-pharmaceuticals-benefit-stabilizing-fluorine.html, XP093287676-
OPPOSITION- Soni Shashank, Deepa Dhiman, "Preparation and in vitro characterization of acetaminophen by solid solution technique ", Journal of Drug Delivery and Therapeutics, (20120101), vol. 2, no. 5, ISSN 2250-1177, pages 71 - 74, XP093287645-
OPPOSITION- "Stability Testing of New Drug Substances and Products Q1A (R2)", INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE, (20030206), pages 1 - 24, INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE, (20160426), XP055268507-
OPPOSITION- Who Drug, "International Nonproprietary Names for Pharmaceutical Substances (INN)", WHO Drug Information, (20160101), vol. 30, no. 3, pages 477 - 481, XP093154325-
OPPOSITION- Peter A. Merkel, "2738: A Randomized Phase 3 Trial Evaluating the Safety and Efficacy of Avacopan in Patients with New or Relapsing Anti-Neutrophil Cytoplasmic Antibody- Associated Vasculitis", Arthritis & Rheumatology, US , (20180901), vol. 70, no. S9, doi:10.1002/art.40700, ISSN 2326-5191, pages 3068 - 3069, XP093154248
OPPOSITION- Tsume Yasuhiro, Mudie Deanna M., Langguth Peter, Amidon Greg E., Amidon Gordon L., "The Biopharmaceutics Classification System: Subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC", European Journal of Pharmaceutical Sciences- Author Manuscript, NL , (20140601), vol. 57, doi:10.1016/j.ejps.2014.01.009, ISSN 0928-0987, pages 1 - 30, XP093287620
OPPOSITION- Reginald-Opara Joy Nneji; Attama Anthony; Ofokansi Kenneth; Umeyor Chukwuebuka; Kenechukwu Frankline, "Molecular interaction between glimepiride and Soluplus®-PEG 4000 hybrid based solid dispersions: Characterisation and anti-diabetic studies", International Journal of Pharmaceutics, AMSTERDAM, NL, (20151112), vol. 496, no. 2, doi:10.1016/j.ijpharm.2015.11.007, ISSN 0378-5173, pages 741 - 750, XP029344073
OPPOSITION- Guo, X. , Rong, Z. , Ying, X., "Calculation of hydrophile-lipophile balance for polyethoxylated surfactants by group contribution method", Journal of Colloid and Interface Science, US , (20060601), vol. 298, no. 1, doi:10.1016/j.jcis.2005.12.009, ISSN 0021-9797, pages 441 - 450, XP005414650
OPPOSITION- SERAJUDDIN, A. T. M., "SOLID DISPERSION OF POORLY WATER-SOUBLE DRUGS: EARLY PROMISES, SUBSEQUENT PROBLEMS, AND RECENT BREAKTHROUGHS.", Journal of pharmaceutical sciences, (19991001), vol. 88, no. 10, doi:10.1021/js980403l, ISSN 0022-3549, pages 1058 - 1066., XP000851882
OPPOSITION- M. Jayne Lawrence, "Surfactant systems: their use in drug delivery", Chemical Society Reviews, UK , (19941201), vol. 23, no. 6, doi:10.1039/cs9942300417, ISSN 0306-0012, pages 417 - 424, XP093154422
OPPOSITION- David R.W. Jayne, "Avacopan for the Treatment of ANCA-Associated Vasculitis", The new England journal of medicine, USA, (20210218), vol. 384, no. 7, doi:10.1056/NEJMoa2023386, pages 599 - 609, XP093154275
OPPOSITION- Shweta Gupta, Rajesh Kesarla, and Abdelwahab Omri, "Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems.", ISRN PHARMACEUTICS, (20131226), vol. 2013, doi:10.1155/2013/848043, ISSN 2090-6145, pages 1 - 16, XP002767351
OPPOSITION- Pirow Bekker, Daniel Dairaghi, Lisa Seitz, Manmohan Leleti, Yu Wang, Linda Ertl, Trageen Baumgart, Sarah Shugarts, Lisa Lohr, Ton Dang, Shichang Miao, Yibin Zeng, Pingchen Fan, Penglie Zhang, Daniel Johnson, Jay Powers, Juan Jaen, Israel Charo, Thomas J. Schall, "Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study", PLOS ONE, (20161021), vol. 11, no. 10, doi:10.1371/journal.pone.0164646, pages 1 - 19, XP055602780
OPPOSITION- David R.W. Jayne, Annette N. Bruchfeld, Lorraine Harper, Matthias Schaier, Michael C. Venning, Patrick Hamilton, Volker Burst, Franziska Grundmann, Michel Jadoul, István Szombati, Vladimír Tesař, Mårten Segelmark, Antonia Potarca, Thomas J. Schall, Pirow Bekker, "Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis", Journal of the American society of nephrology, (20170901), vol. 28, no. 9, doi:10.1681/ASN.2016111179, ISSN 1046-6673, pages 2756 - 2767, XP055602776
OPPOSITION- Anna Czajkowska-Kośnik, "Development and Evaluation of Liquid and Solid Self-Emulsifying Drug Delivery Systems for Atorvastatin", Molecules, vol. 20, no. 12, doi:10.3390/molecules201219745, pages 21010 - 21022, XP055397258
OTHER- Pirow Bekker, Daniel Dairaghi, Lisa Seitz, Manmohan Leleti, Yu Wang, Linda Ertl, Trageen Baumgart, Sarah Shugarts, Lisa Lohr, Ton Dang, Shichang Miao, Yibin Zeng, Pingchen Fan, Penglie Zhang, Daniel Johnson, Jay Powers, Juan Jaen, Israel Charo, Thomas J. Schall, "Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study", PLOS ONE, vol. 11, no. 10, doi:10.1371/journal.pone.0164646, page e0164646, XP055602780
OTHER- David R.W. Jayne, Annette N. Bruchfeld, Lorraine Harper, Matthias Schaier, Michael C. Venning, Patrick Hamilton, Volker Burst, Franziska Grundmann, Michel Jadoul, István Szombati, Vladimír Tesař, Mårten Segelmark, Antonia Potarca, Thomas J. Schall, Pirow Bekker, "Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis", Journal of the American Society of Nephrology, US , (20170901), vol. 28, no. 9, doi:10.1681/ASN.2016111179, ISSN 1046-6673, pages 2756 - 2767, XP055602776
SEARCH- PIROW BEKKER ET AL, "Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study", PLOS ONE, (20161021), vol. 11, no. 10, doi:10.1371/journal.pone.0164646, page e0164646, XP055602780 [A] 1-15 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents